Biochemical and Biophysical Research Communications
miR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma
Introduction
Papillary thyroid carcinoma (PTC) is the most common histotype of thyroid malignancy, and its incidence has been steadily increasing over the past few decades [1], [2]. Although the majority of cases have excellent prognosis and therapeutic response, up to 30% of patients present with locoregional recurrence or distant metastases within 10 years [3], [4]. Thus, it is imperative to understand the molecular basis of PTC in order to develop effective diagnostic, prognostic, and therapeutic strategies for its treatment.
microRNAs (miRNAs) are 18–25-nt, non-coding, single-stranded RNAs that regulate gene expression at the post-transcriptional level by binding to the 3′-untranslated region (UTR) of target mRNAs [5], [6]. miRNAs regulate a variety of basic physiological processes, including the cell cycle, apoptosis, cell proliferation, migration, invasion, and differentiation [7], [8], [9], [10], and miRNA expression or function is dysregulated in various types of malignancies, including PTC [11]. For instance, overexpression of the tumor suppressor miR-146a decreased PTC cell survival and induced PTC cell apoptosis [12], while miR-199a-3p is downregulated in PTC and its overexpression in PTC cells inhibited migration and proliferation, thereby inducing cell death [1]. On the other hand, miR-222 and miR-146b levels are upregulated in recurrent PTC and serve as circulating biomarkers for this cancer [3]. A recent microarray analysis revealed that miR-204-5p was downregulated in PTC [13]; however, the functional significance of this observation is not known.
In the present study, we validated that miR-204-5p was obviously downregulated in PTC tissues and cell lines. miR-204-5p overexpression suppressed PTC cell growth and induced cell cycle arrest and apoptosis. Insulin-like growth factor-binding protein 5 (IGFBP5) was identified as a direct target of miR-204-5p regulation, and restoring IGFBP5 expression partially reversed the antitumorigenic effects of miR-204-5p.
Section snippets
Cell lines and tissues
Human PTC cell lines (TCP-1 and BCPAP) and HEK293T were cultured in Dulbecco's Modified Eagle's Medium (HyClone/Thermo Scientific, Beijing, China) supplemented with 10% fetal bovine serum at 37 °C in 5% CO2. Cells were passaged every 2–3 days. PTC and adjacent non-tumorous tissue samples were obtained with informed consent from 16 PTC patients who underwent curative resection at Shanghai Pudong Gongli Hospital. The study protocol was approved by the Ethics Committee of Shanghai Pudong Gongli
miR-204-5p expression is downregulated in PTC tissues and cell lines
miR-204-5p expression in 16 sets of PTC and adjacent normal tissue was assessed by qRT-PCR. miR-204-5p expression was downregulated in PTC relative to adjacent non-tumorous tissues (Fig. 1A). Similarly, miR-204-5p levels were reduced in the TPC-1 and BCPAP PTC cell lines as compared to normal tissue (Fig. 1B). These data indicate that miR-204-5p expression is attenuated in PTC.
miR-204-5p suppresses proliferation and promotes apoptosis in PTC cells
To investigate the biological function of miR-204-5p in PTC, TPC-1 and BCPAP cells were infected with a lentivirus
Discussion
miRNAs play critical roles in the initiation, promotion, and progression of human cancers by regulating target gene expression [15], [16]; as such, they can be functionally distinguished as tumor suppressors or oncogenes [17]. As a tumor suppressor, miR-204-5p is downregulated in minimal deviation adenocarcinoma [18], clear cell renal cell carcinoma [19], gastric cancer arising from Helicobacter pylori infection [20], and melanoma [21]. A recent study also found that miR-204-5p was frequently
Conflict of interest
The authors declare no conflict of interest.
Acknowledgments
This work was supported by Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PDWxq2014-9) and Shanghai Science and Technology Commission (15ZR1437100).
References (35)
- et al.
miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2
Cancer Lett.
(2013) - et al.
IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma
Cancer Lett.
(2013) - et al.
Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma
J. Hepatol.
(2008) - et al.
Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo
J. Biol. Chem.
(2003) - et al.
Differential expression of IGFBP-5 and two human ESTs in thyroid glands with goiter, adenoma and papillary or follicular carcinomas
Cancer Lett.
(2003) - et al.
miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma
Oncotarget
(2014) - et al.
Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005
Cancer Epidemiol. Biomarkers Prev.
(2009) - et al.
MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer
Cancer
(2013) - et al.
Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances
Thyroid
(2009) - et al.
Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer
J. Natl. Cancer Inst.
(2013)
Gene regulation by transcription factors and microRNAs
Science
MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2
J. Pathol.
miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer
Oncogene
MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival
Oncogene
miR-27a regulates endothelial differentiation of breast cancer stem like cells
Oncogene
MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance
Mol. Cancer Ther.
MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development
Int. J. Cancer
Cited by (101)
Insulin-like growth factor (IGF) performance in ovarian function and applications in reproductive biotechnologies
2023, Growth Hormone and IGF ResearchMiR-204-5p-targeted AP1S2 is necessary for papillary thyroid carcinoma
2023, Molecular and Cellular EndocrinologyEpigenetic signature associated with thyroid cancer progression and metastasis
2022, Seminars in Cancer BiologyCitation Excerpt :A number of other studies have further established the tumor suppressive effect of miRNAs in PTC. Such miRNAs include miR-219-5p which targets estrogen receptor alpha [55] and EYA2 [56]; miR-31 which targets RNA-binding protein HuR [57]; miR-204-5p which targets IGFBP5 [58]; miR-126 which targets low-density lipoprotein receptorrelated protein 6 (LRP6) [59]; miR-29a [60] and miR-497 [61] both of which target Akt3; miR-375 with targets ERBB2 [62], miR-663 which targets TGFβ1 [63], miR-137 which targets CXCL12 [64]; miR-486-5p which targets fibrillin-1 [65]; miR-613 [66] and miR-577 [67] both of which target SphK2; miR-7 which targets CKS2 [68]; miR-195 which targets CCND1 and FGF2 [69]; miR-148a which targets STAT3 [70]; let-7b which targets HMGA2 [71]; miR-335 which targets ZEB2 [72]; miR-139 which targets fibronectin 1 [73]; miR-144 which targets WWTR1 [74]; miR-199a-5p which targets SNAI1 [48]; miR-622 which targets VEGF [75]; miR-361-5p which targets rho-associated coiled-coil kinase 1 (ROCK1) [76]; miR-4728 which targets MAPK [77]; miR-9 which targets BRAF [78]; miR-143-3p which targets MSI2 [79], miR-1266 which targets FGFR2 [80]; miR-188-5p which targets FGF5 [81], miR-384 which targets PRKACB [82], miR-873-5p which targets CXCL16 [83], miR-1256 which targets 5-hydroxytryptamine receptor 3A (HTR3A) [84], miR-326 which targets MAPK1 and ERBB4 [85], miR-381-3p which targets LRP6 [86] and miR-873 which is a target of circular RNA circFAT1(e2) [87]. Not just the papillary thyroid cancer, but the researchers have been interested in dysregulated miRNAs in anaplastic thyroid cancer (ATC) as well, for more than a decade now.
Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation
2022, Current Research in Pharmacology and Drug Discovery
- 1
These authors contributed equally to this work.